CD274 and non-small cell lung carcinoma: Non‐small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide.1 Immune checkpoint inhibitors (ICIs) have been recently used as a new strategy for treatment in various malignancies.2, 3 Several clinical trials demonstrated that treatment with antiprogrammed cell death 1 (PD‐1)/PD‐ligand 1 (PD‐L1) antibodies showed a promising efficacy.4, 5, 6, 7